Research programme: antidotes for nerve agents - Nutra Pharma Corporation/International Security Group

Drug Profile

Research programme: antidotes for nerve agents - Nutra Pharma Corporation/International Security Group

Alternative Names: Nerve agent countermeasures - Nutra Pharma Corporation/International Security Group

Latest Information Update: 15 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Nutra Pharma Corporation
  • Class Antidotes
  • Mechanism of Action Cholinergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Poisoning

Most Recent Events

  • 24 May 2017 Nutra Pharma Corporation and International Security Group enter into collaboration for the development of nerve agent countermeasures
  • 24 May 2017 Preclinical trials in Poisoning in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top